

Risk of Advanced-Stage Breast Cancer among Older Women with Comorbidities

Shagufta Yasmeen¹, Rebecca A. Hubbard², Patrick S. Romano¹, Weiwei Zhu², Berta M. Geller³, Tracy Onega⁴, Bonnie C. Yankaskas⁵, Diana L. Miglioretti², and Karla Kerlikowske⁶

Abstract

Background: Comorbidities have been suggested influencing mammography use and breast cancer stage at diagnosis. We compared mammography use, and overall and advanced-stage breast cancer rates, among female Medicare beneficiaries with different levels of comorbidity.

Methods: We used linked Breast Cancer Surveillance Consortium (BCSC) and Medicare claims data from 1998 through 2006 to ascertain comorbidities among 149,045 female Medicare beneficiaries ages 67 and older who had mammography. We defined comorbidities as either "unstable" (life-threatening or difficult to control) or "stable" (age-related with potential to affect daily activity) on the basis of claims within 2 years before each mammogram.

Results: Having undergone two mammograms within 30 months was more common in women with stable comorbidities (86%) than in those with unstable (80.3%) or no (80.9%) comorbidities. Overall rates of advanced-stage breast cancer were lower among women with no comorbidities [0.5 per 1,000 mammograms, 95% confidence interval (CI), 0.3–0.8] than among those with stable comorbidities (0.8; 95% CI, 0.7–0.9; $P = 0.065$ compared with no comorbidities) or unstable comorbidities (1.1; 95% CI, 0.9–1.3; $P = 0.002$ compared with no comorbidities). Among women having undergone two mammograms within 4 to 18 months, those with unstable and stable comorbidities had significantly higher advanced cancer rates than those with no comorbidities ($P = 0.004$ and $P = 0.03$, respectively).

Conclusions: Comorbidities were associated with more frequent use of mammography but also higher risk of advanced-stage disease at diagnosis among the subset of women who had the most frequent use of mammography.

Impact: Future studies need to examine whether specific comorbidities affect clinical progression of breast cancer. *Cancer Epidemiol Biomarkers Prev*; 21(9); 1510–9. ©2012 AACR.

Introduction

Breast cancer screening among older women is complicated because of the variation in the number and severity of comorbidities (1). Studies examining the associations between comorbid conditions and mammogra-

phy screening use and breast cancer outcomes have reported mixed results (2). Some have reported a higher risk of advanced-stage cancer among women with comorbidities (3), whereas others have reported a higher risk of advanced-stage cancer at diagnosis among women with no comorbidities (4, 5). Age-related comorbid conditions may increase the frequency of physician visits, leading to higher mammography use and better follow-up of abnormal results, resulting in an earlier stage at diagnosis (6). Alternatively, chronic disease management may constitute a "competing demand" during physician visits, diverting attention from the delivery of preventive services. A recent study of Medicare beneficiaries suggests that stable comorbidities are associated with lower likelihood of late-stage diagnosis, whereas unstable comorbidities are associated with higher likelihood of late-stage diagnosis, partially due to less use of mammography (7).

Many cancer screening guidelines recommend considering an older woman's health care status when making screening decisions, as screening mammography is unlikely to benefit older women whose life expectancy is less than 5 years (8, 9). However, it is unclear that how

Authors' Affiliations: ¹University of California Davis School of Medicine, Sacramento, California; ²Group Health Research Institute, Group Health Cooperative, Seattle, Washington; ³Health Promotion Research, University of Vermont, College of Medicine, Burlington, Vermont; ⁴Department of Community and Family Medicine, Dartmouth Medical School, Norris Cotton Cancer Center, Lebanon, New Hampshire; ⁵Department of Radiology, University of North Carolina, Chapel Hill, North Carolina; and ⁶Department of Epidemiology and Biostatistics and General Internal Medicine Section, Department of Veterans Affairs, University of California, San Francisco, California

Note: Supplementary data for this article are available at Cancer Epidemiology, Biomarkers & Prevention Online (<http://cebp.aacrjournals.org/>).

Corresponding Author: Shagufta Yasmeen, Department of Obstetrics/Gynecology and Internal Medicine, University of California Davis, 4860 Y Street, Suite 2500, Sacramento, CA 95817. Phone: 91-734-6929; Fax: 916-734-6666; E-mail: shagufta.yasmeen@ucdmc.ucdavis.edu

doi: 10.1158/1055-9965.EPI-12-0320

©2012 American Association for Cancer Research.

these guidelines are applied in practice and to what extent cancer screening tests are actually targeted to healthy older women with sufficient life expectancy to reasonably benefit from screening mammography, and not offered to older women with multiple or severe comorbidities who have a life expectancy of less than 5 years and are unlikely to benefit from screening (10, 11).

Previous studies have used the linked Surveillance, Epidemiology, and End Results (SEER) program-Medicare data to assess comorbidities, mammography use, and breast cancer outcomes in older women (12). A major limitation of these data is difficulty in distinguishing screening from diagnostic mammograms in cancer case cohorts (13), given that most women eventually undergo diagnostic mammography evaluation before treatment begins. For instance, mammograms conducted to evaluate breast symptoms can be mislabeled as screening instead of diagnostic, especially in older women with comorbidities who may not undergo regular screening mammography. Such misclassification can lead to overestimation of screening mammography usage and may thereby bias epidemiologic analyses of factors associated with adequate screening. Claims-based algorithms to minimize this misclassification risk are useful but not entirely satisfactory (13).

The goal of this study was to determine whether the presence and severity of comorbid conditions affect screening mammography use and breast cancer stage at diagnosis. We examined data from 4 mammography registries in the Breast Cancer Surveillance Consortium (BCSC; ref. 14) and linked Medicare claims data from 1998 to 2006 to estimate the relationship between the presence and severity of comorbid conditions and use of mammography, breast cancer stage at diagnosis, and tumor characteristics. We used an updated approach to classifying comorbidities that has been shown to separate comorbidities associated with increased versus decreased mammography use in the Medicare population (7).

Materials and Methods

Data source

The BCSC is a collaborative effort between 7 geographically dispersed mammography registries (14). Details about the BCSC have been provided elsewhere (15, 16). Data were obtained from 4 BCSC mammography registries (Carolina Mammography Registry, New Hampshire Mammography Network, San Francisco Mammography Registry, and Vermont Breast Cancer Surveillance System) that participated in linking BCSC records and Medicare claims data. Registries collected demographic, risk factor, and clinical information at each mammogram, including radiologists' indication for examination and recommendations based on the American College of Radiology's Breast Imaging Reporting and Data System (BI-RADS). Data were pooled at a central Statistical Coordinating Center (SCC) at Group Health Research Institute (Seattle, WA; ref. 14, 16). BCSC registries and the SCC

received Institutional Review Board approval for active or passive consenting processes or a waiver of consent to enroll participants, link data, and conduct analysis. All procedures were Health Insurance Portability and Accountability Act (HIPAA) compliant, and registries and the SCC received a Federal Certificate of Confidentiality and other protection for the identities of women, physicians, and facilities.

Women participating in these 4 mammography registries who were also enrolled in Medicare were linked to the Center for Medicare & Medicaid Services' (CMS) Medicare Program Master Enrollment file by identifiers such as name, date of birth, and social security number. Breast cancer diagnoses and tumor characteristics were obtained through linkage with state tumor registries or regional SEER programs (17) and additional linkage to hospital-based pathology services at 3 of the 4 mammography registries (16).

Study population

The study population included all women who were 67 years of age and older who had undergone mammography in the BCSC database from the 4 sites between January 1, 2000, and December 31, 2006. We limited the study to women with at least 2 years of continuous Medicare enrollment in part A and part B and who were not enrolled in Medicare Advantage for 2 years before a mammogram in the BCSC database and with no previous history of breast cancer. We required 2 years of continuous Medicare enrollment before a mammogram to ensure complete capture of claims during the period used to assess presence of comorbidities. To further ensure complete capture of Medicare claims, we excluded mammograms included in the BCSC database for which a corresponding Medicare claim for a mammogram could not be found within 7 days before or after the examination date recorded in the BCSC database. Approximately 426,295 mammograms meeting inclusion criteria were identified in the BCSC database from 2000 to 2006 and 415,078 (97.4%) had a matching Medicare mammogram claim within 7 days of BCSC examination date. Of those with matching mammogram claims, 3,316 (2.2%) had a breast cancer diagnosis within 12 months of mammography.

Measurements and definitions

We characterized each mammogram included in the study according to type of examination (screening vs. diagnostic) and time interval between that examination and a woman's most recent prior examination. A screening mammogram was defined using the standard BCSC definition as a bilateral mammogram with a physician-stated indication for routine screening and no mammography within the past 9 months. Mammography intervals were categorized as 4 to 18 months, 19 to 30 months, or 31 to 42 months (15, 16, 18). Estimates for the number of months between mammograms were calculated by using the most recent of the dates of previous mammography in the BCSC database or the

self-reported date given by the participant. All mammograms occurring within a 4-month period were considered to represent a single diagnostic series, and our analyses included only the first mammogram in the series.

We applied a recently refined list of 38 comorbid conditions (7), classified by organ system and severity, using ICD-9-CM codes listed in previously published comorbidity measures developed for Medicare claims data by Klabunde and colleagues (19), Fleming and colleagues (12), and Elixhauser and colleagues (20). We updated these measures to more recent versions of ICD-9-CM and distinguished "stable" and "unstable" comorbidities on the basis of clinical significance, judgment of seriousness, and whether the condition predicted 5-year mortality in prior studies. This distinction was previously shown to be useful in understanding variation in mammography use (7). We defined comorbidities that are life-threatening or difficult to control such as severe heart failure, cardiac arrhythmias, and end-stage liver disease as "unstable," and age-related conditions that could affect daily function, such as arthritis, osteoporosis, depression, and diabetes as "stable" (Supplementary Data S1).

Inpatient, outpatient, and physician-supplier claims were reviewed for 2 years before the most recent mammogram in the BCSC database and used to determine the prevalence of comorbidities during that period, excluding the month of diagnosis in cancer cases. If a qualifying comorbid diagnosis code appeared only once in physician claims during that period and an identical code was not present in inpatient hospital claims, then the condition was not counted as a comorbidity (21). Likewise, if a code appeared more than once in physician claims within a 30-day period but never appeared again in either inpatient hospital or physician claims, then the condition was not counted (22). This approach was based on prior studies showing poor agreement between medical records and Medicare claims when looser methods were used to capture diagnostic information (21, 22).

To estimate total comorbidity burden, we grouped stable and unstable comorbidities as absent or present. We then counted the number of stable comorbid conditions. Unstable comorbidities were collapsed into a single group, as the prevalence of multiple unstable conditions was very low.

Breast cancer stage at diagnosis was classified according to the tumor, node, metastasis (TNM) system on the basis of the criteria of the American Joint Committee on Cancer as stage 0, I, IIA, IIB, III, or IV. Invasive tumors of stages IIB, III, and IV were considered to be advanced-stage disease (23). This definition of advanced-stage disease has been used as a proxy outcome among women with breast cancer because only 5% to 12% of stage I/II patients die within 10 years after diagnosis, compared with more than 60% of stage III patients and more than 90% of stage IV patients (24).

Statistical analysis

We estimated the overall prevalence of stable and unstable comorbidities in our study population. We summarized demographic characteristics stratified by comorbidity status: no comorbid conditions, stable conditions only (aggregating women with one or more conditions, due to their similar characteristics), or unstable conditions with or without additional stable conditions. Among women diagnosed with cancer, demographic characteristics, comorbidity burden, mammography use rates, and tumor characteristics were compared between comorbidity groups using χ^2 tests with statistical significance defined at $P < 0.05$.

We calculated stratum-specific frequency distributions for previous mammography use based on a single mammogram per woman to prevent overrepresentation of women who were frequent mammography users (15). We selected the mammogram closest to the date of diagnosis for cancer cases and a randomly selected mammogram for non-cancer cases. For mammograms followed by a cancer diagnosis, we calculated the proportion of tumors that were invasive and the distribution of tumor size, stage, grade, and estrogen receptor status.

We explored differences in previous mammography use by comorbidity status using logistic regression models for the binary outcome "adequately screened," which we defined as having 2 mammography examinations within 30 months. This model was adjusted for age, race/ethnicity, year, and BCSC registry. In this analysis, we selected one mammogram to include in the analysis per woman as described above.

We used logistic regression to estimate overall and advanced cancer rates per 1,000 mammograms by comorbidity status, adjusting for age, race/ethnicity, year of diagnosis, and BCSC registry using generalized estimating equations (GEE). In these analyses, we excluded diagnostic mammograms with no prior mammogram within 42 months. The unit of analysis in these models was the mammogram, with women potentially contributing multiple mammograms. The method of GEE accounts for clustering among mammograms from the same woman. Adjusted cancer rates were estimated using the method of indirect standardization (25, 26). Confidence intervals (CI) were estimated using the delta method. Models were also fit including interaction terms for previous mammography use and comorbidity status to examine variation in the association between comorbidity status and cancer rates across previous mammography use groups. Adjusted cancer rates from these models are reported for each comorbidity and previous mammography use group. We also computed the mean time from the most recent prior mammography examination to cancer diagnosis to evaluate possible diagnostic delays among women by comorbidity status. All statistical analyses were carried out using R statistical software.

Results

We identified 415,078 eligible mammograms among 149,045 women between 2000 and 2006 in the linked BCSC-Medicare data (Table 1). Comorbidities were identified in 133,227 (89.4%) women: 93,428 (62.7%) had stable and 39,799 (26.7%) had unstable or both stable and unstable comorbidities. Overall, 83.9% of women had 2 mammograms within 30 months; these proportions were

slightly higher among those with stable comorbidities (86.0%) than among those with no comorbidities (80.9%) or unstable comorbidities (80.3%; Table 1). The Supplementary Data show the prevalence of stable comorbidities by organ system.

A total of 3,316 (2.2%) women were diagnosed with primary incident breast cancer (Table 2). Comorbidities were identified in 89.4% of the cancer cohort; 60.8% had

Table 1. Characteristics of female Medicare beneficiaries who underwent mammography examinations in the linked BCSC-Medicare data, 2000–2006 ($N = 149,045$)

	All women <i>n</i> (%)	No comorbidities (<i>N</i> = 15,818) <i>n</i> (%)	Stable ^a comorbidities (<i>N</i> = 93,428) <i>n</i> (%)	Unstable ^b only or both stable and unstable comorbidities (<i>N</i> = 39,799) <i>n</i> (%)
Age at mammography examination, y				
67–74	82,777 (55.5)	10,894 (68.9)	52,567 (56.3)	19,316 (48.5)
75–79	34,836 (23.4)	3,042 (19.2)	21,659 (23.2)	10,135 (25.5)
80–84	20,998 (14.1)	1,387 (8.8)	12,862 (13.8)	6,749 (17.0)
>85	10,434 (7.0)	495 (3.1)	6,340 (6.8)	3,599 (9.0)
Race/ethnicity				
White	114,181 (76.6)	12,863 (81.3)	72,438 (77.5)	28,880 (72.6)
Black	11,957 (8.0)	737 (4.7)	6,903 (7.4)	4,317 (10.8)
Hispanic	2,505 (1.7)	252 (1.6)	1,542 (1.7)	711 (1.8)
Asian/PI	5,277 (3.5)	440 (2.8)	3,442 (3.7)	1,395 (3.5)
American-Indian	868 (0.6)	51 (0.3)	448 (0.5)	369 (0.9)
Other/unknown	14,257 (9.6)	1,475 (9.3)	8,655 (9.3)	4,127 (10.4)
Number of comorbid conditions				
None (0)	15,818 (10.6)	15,818 (100)	—	—
1	24,426 (16.4)	—	23,907 (25.6)	519 (1.3)
2	26,761 (18.0)	—	24,523 (26.2)	2,238 (5.6)
3	22,951 (15.4)	—	18,680 (20.0)	4,271 (10.7)
4	17,310 (11.6)	—	12,008 (12.9)	5,302 (13.3)
5	12,125 (8.1)	—	6,770 (7.2)	5,355 (13.5)
>5	29,654 (19.9)	—	7,540 (8.1)	22,114 (55.6)
Mammography use (time between mammography examinations) ^c				
4–18 m	92,536 (67.3)	9,251 (64.1)	60,718 (70.0)	22,567 (62.4)
19–30 mo	22,746 (16.6)	2,426 (16.8)	13,848 (16.0)	6,472 (17.9)
31–42 mo	8,529 (6.2)	969 (6.7)	4,886 (5.6)	2,674 (7.4)
>42 mo or first screen ^d	11,893 (8.7)	1,575 (10.9)	6,481 (7.5)	3,837 (10.6)
>42 mo or first diagnostic ^e	1,710 (1.2)	209 (1.4)	858 (1)	643 (1.8)

Abbreviation: PI, Pacific Islander.

^aStable comorbidities are defined as age-related conditions with no influence on predicted 5-year mortality. Examples include arthritis, osteoporosis, depression, diabetes, thyroid disorders, stable coronary artery disease, and peptic ulcer disease (Supplementary Data S1).

^bUnstable comorbidities are defined as life-threatening or difficult to control with less than 5-year predicted mortality. Examples include severe heart failure, end-stage pulmonary disease, end-stage liver disease, renal disease, and diabetes with complications (Supplementary Data S1).

^cMammography use was categorized according to type of examination and time between mammography examinations. Time to prior mammogram was calculated using last mammogram before cancer diagnosis for women with a cancer diagnosis and a randomly selected mammogram for women with no cancer diagnosis.

^dMore than 42 months or first screen is defined as a screening mammogram with no prior mammogram within 42 months.

^eMore than 42 months or first diagnostic is defined as a diagnostic mammogram with no prior within 42 months.

Table 2. Characteristics of female Medicare beneficiaries diagnosed with breast cancer in the linked BCSC-Medicare data, 2000–2006 (N = 3,316)

	All cancer cases n(%)	No comorbidities (N = 350) n(%)	Stable ^a comorbidities (N = 2,018) n(%)	Unstable ^b only or both stable and unstable comorbidities (N = 948) n(%)	P
Age at diagnosis, y					
67–74	1,516 (45.7)	192 (54.9)	942 (46.7)	382 (40.3)	<0.001
75–79	918 (27.7)	95 (27.1)	538 (26.7)	285 (30.1)	
80–84	562 (16.9)	42 (12)	346 (17.1)	174 (18.4)	
>85	320 (9.7)	21 (6)	192 (9.5)	107 (11.3)	
Race/ethnicity					<0.0159
White	2,628 (79.3)	296 (84.6)	1,610 (79.8)	722 (76.2)	<0.001
Black	270 (8.1)	19 (5.4)	161 (8)	90 (9.5)	
Other/unknown ^c	418 (12.6)	35 (10.0)	247 (12.2)	136 (14.3)	
Number of comorbid conditions					<0.001
None (0)	350 (10.6)	350 (100)	—	—	<0.001
1	553 (16.7)	—	545 (27)	55 (5.8)	
2	580 (17.5)	—	533 (26.4)	—	
3	506 (15.3)	—	396 (19.6)	110 (11.6)	
4	354 (10.7)	—	244 (12.1)	110 (11.6)	
5	276 (8.3)	—	149 (7.4)	127 (13.4)	
>5	697 (21)	—	151 (7.5)	546 (57.6)	
Mammography use (time between mammography examinations) ^d					<0.001
4–18 mo	1,898 (63.0)	164 (54.5)	1,240 (66.7)	494 (58.1)	<0.001
19–30 mo	425 (14.1)	42 (14.0)	259 (13.9)	124 (14.6)	
31–42 mo	157 (5.2)	14 (4.7)	91 (4.9)	52 (6.1)	
>42 mo or first screen ^e	249 (8.3)	33 (11.0)	138 (7.4)	78 (9.2)	
>42 mo or first diagnostic ^f	282 (9.4)	48 (15.9)	132 (7.1)	102 (12.0)	
Tumor characteristics					0.479
<i>In situ</i>	501 (15.1)	49 (14.0)	317 (15.7)	135 (14.2)	0.001
Invasive	2,814 (84.9)	301 (86.0)	1,700 (84.3)	813 (85.8)	
Stage ^g					0.001
I	1,458 (59.8)	138 (53.1)	922 (61.9)	398 (57.6)	0.028
IIA	519 (21.3)	69 (26.5)	308 (20.7)	142 (20.5)	
IIB	195 (8.0)	20 (7.7)	97 (6.5)	78 (11.3)	
III, IV	268 (11.0)	33 (12.7)	162 (10.9)	73 (10.6)	0.034
Tumor size, mm					
<10	854 (29.2)	81 (26.8)	540 (30.2)	233 (27.9)	
11–15	860 (29.4)	86 (28.5)	549 (30.7)	225 (26.9)	0.761
≥16	1,210 (41.2)	135 (44.7)	697 (39)	378 (45.2)	
Tumor grade					0.034
Well-differentiated	610 (23.0)	81 (29.9)	370 (22.8)	159 (20.9)	0.761
Moderately differentiated	1,233 (46.4)	112 (41.3)	768 (47.3)	353 (46.4)	
Poorly differentiated/undifferentiated	812 (30.6)	78 (28.8)	485 (29.9)	248 (32.6)	
ER status					0.761
Positive	1,964 (84.5)	202 (85.6)	1,194 (84.1)	568 (85.0)	0.761
Negative	360 (15.5)	34 (14.4)	226 (15.9)	100 (15.0)	

^aStable comorbidities are defined as age-related conditions with no influence on predicted 5-year mortality. Examples include arthritis, osteoporosis, depression, diabetes, thyroid disorders, stable coronary artery disease, and peptic ulcer disease (Supplementary Data S1).

^bUnstable comorbidities are defined as life-threatening or difficult to control with less than 5-year predicted mortality. Examples include severe heart failure, end-stage pulmonary disease, end-stage liver disease, renal disease, and diabetes with complications (Supplementary Data S1).

^cGroups collapsed because of small cell sizes.

^dMammography use was categorized according to type of examination and time between mammography examinations. Time to prior mammogram was calculated using last mammogram before cancer diagnosis for women with a cancer diagnosis and a randomly selected mammogram for women with no cancer diagnosis.

^eMore than 42 months or first screen is defined as a screening mammogram with no prior mammogram within 42 months.

^fMore than 42 months years or first diagnostic is defined as a diagnostic mammogram with no prior within 42 months.

^gBreast cancer stage at diagnosis is classified on TNM staging system (tumor, node, and metastasis) which is based on the criteria of the American Joint Commission. Stage distribution was computed among invasive tumors only.

stable comorbidities and 28.6% had unstable only or both stable and unstable comorbidities. Women with comorbidities were significantly older and more likely to have recent mammography than women with no comorbidities ($P < 0.001$; Table 2). Overall, 77.1% of these women had a mammogram within 4 to 30 months of cancer diagnosis; these proportions were lower among women with no comorbidities (68.5%) and higher among those with stable (80.6%) or unstable comorbidities (72.7%; $P < 0.001$).

Overall, 84.9% of the tumors detected were invasive and 15.1% were ductal carcinoma *in situ*. Among women with invasive cancers, those with stable comorbidities had significantly higher proportions of stage I cancers and women with unstable and stable comorbidities had the highest proportions of stage IIB tumors than women with no comorbidities. Women with unstable or no comorbidities had a higher proportion of advanced-stage cancers than those with stable comorbidities (21.8% and 20.4% vs. 17.3%, respectively). Women with no comorbidities showed higher prevalence of well-differentiated tumors than women with stable and unstable comorbidities ($P = 0.034$; Table 2).

As displayed in Table 3, overall women with stable comorbidities were more likely to have had a mammogram within 4 to 18 months than women with either unstable or no comorbidities (70% vs. 62.4% and

64.1%), respectively, and this pattern was similar among women younger than 75 and 75 years and older.

Overall, the presence of either stable or unstable comorbidities was associated with significantly higher odds of adequate mammography use (defined as a prior mammogram within 30 months) after adjusting for patient characteristics (age, race, year, and BCSC registry). The OR for adequate mammography use among women with stable comorbidities compared with no comorbidities was 1.60 (95% CI, 1.52–1.67) and for unstable comorbidities compared with no comorbidities was 1.14 (95% CI, 1.08–1.19).

Adjusted overall breast cancer rates (ductal carcinoma *in situ* and invasive combined) and advanced-stage cancer rates per 1,000 mammograms by comorbidity status and prior mammography use are displayed in Table 4. Overall cancer rates per 1,000 mammograms are highest among women with unstable comorbidities (7.5; 95% CI, 7.0–8.1) and lower among women with stable comorbidities (6.7; 95% CI, 6.4–7.0) or no comorbidities (6.6; 95% CI, 5.8–7.5). On comparing cancer rates per 1,000 mammograms by comorbidity status, there were no significant differences in cancer rates among women with stable and unstable comorbidities compared with women with no comorbidities (Table 4). Women were more likely to be diagnosed with breast cancer when mammogram intervals were

Table 3. Mammography examinations by comorbidity status among female Medicare beneficiaries in the linked BCSC-Medicare data, 2000–2006 ($N = 149,045$)

Mammography use ^a	1 y (4–18 mo) n (%)	2 y (19–30 mo) n (%)	3 y (31–42 mo) n (%)	>42 mo or first screening mammogram ^d n (%)	>42 mo or first diagnostic mammogram ^e n (%)
All					
Stable ^b comorbidities	60,718 (70)	13,848 (16)	4,886 (5.6)	6,481 (7.5)	858 (1)
Unstable ^c comorbidities	22,567 (62.4)	6,472 (17.9)	2,674 (7.4)	3,837 (10.6)	643 (1.8)
No comorbidities	9,251 (64.1)	2,426 (16.8)	969 (6.7)	1,575 (10.9)	209 (1.4)
Age < 75					
Stable ^b comorbidities	35,874 (72.8)	7,477 (15.2)	2,482 (5.0)	3,104 (6.3)	330 (0.7)
Unstable ^c comorbidities	11,670 (65.5)	3,111 (17.2)	1,235 (6.9)	1,594 (8.9)	220 (1.2)
No comorbidities	6,638 (66.1)	1,642 (16.4)	635 (6.3)	1,002 (10.0)	118 (1.2)
Age > 75					
Stable ^b comorbidities	24,844 (66.2)	6,371 (17.0)	2,404 (6.4)	3,377 (9.0)	528 (1)
Unstable ^c comorbidities	10,897 (59.3)	3,361 (18.3)	1,439 (7.8)	2,243 (12.2)	423 (2)
No comorbidities	2,613 (59.5)	784 (17.8)	334 (7.6)	573 (13.0)	91 (2)

^aMammography use was categorized according to type of examination and time between mammography examination.

^bStable comorbidities are defined as age-related conditions with no influence on predicted 5-year mortality. Examples include arthritis, osteoporosis, depression, diabetes, thyroid disorders, stable coronary artery disease, and peptic ulcer disease (Supplementary Data S1).

^cUnstable comorbidities are defined as life-threatening or difficult to control with less than 5-year predicted mortality. Examples include severe heart failure, end-stage pulmonary disease, end-stage liver disease, renal disease, and diabetes with complications (Supplementary Data S1).

^dMore than 42 months or first screen is defined as a screening mammogram with no prior mammogram within 42 months.

^eMore than 42 months or first diagnostic is defined as a diagnostic mammogram with no prior within 42 months.

Table 4. Overall breast cancer rates per 1,000 mammograms by comorbidity status and time to previous mammogram ($N = 3,316$)

	Overall			4–18 mo			19–30 mo			31–42 mo			>42 mo/first screening ^c		
	Rate (95% CI)	P	Rate (95% CI)	P	Rate (95% CI)	P	Rate (95% CI)	P	Rate (95% CI)	P	Rate (95% CI)	P	Rate (95% CI)	P	
All	6.9 (6.6–7.2)	—	6.1 (5.9–6.4)	—	8.1 (7.8–8.9)	—	9.9 (8.5–11.6)	—	14.6 (13.4–15.9)	—	14.6 (13.4–15.9)	—	14.6 (13.4–15.9)	—	
No comorbidities	6.6 (5.8–7.5)	Ref	5.7 (4.9–6.6)	Ref	8.0 (5.9–10.8)	Ref	8.0 (4.7–13.5)	Ref	14.6 (10.4–20.4)	Ref	14.6 (10.4–20.4)	Ref	14.6 (10.4–20.4)	Ref	
Stable ^a comorbidities	6.7 (6.4–7.0)	0.821	6.0 (5.7–6.4)	0.489	8.0 (7.1–9.0)	0.76	9.9 (8.0–12.1)	0.60	14.7 (12.4–17.3)	0.60	14.7 (12.4–17.3)	0.60	14.7 (12.4–17.3)	0.60	
Unstable ^b comorbidities	7.5 (7.0–8.1)	0.084	6.6 (6.1–7.2)	0.086	8.3 (7.0–10)	0.58	10.8 (8.3–14.2)	0.63	14.5 (11.6–18.1)	0.63	14.5 (11.6–18.1)	0.63	14.5 (11.6–18.1)	0.481	

NOTE: Results adjusted for covariates (age, race/ethnicity/BCSC registry). Mammography use was categorized according to type of examination and time between mammography examination. Time to prior mammogram was calculated using last mammogram before cancer diagnosis for women with a cancer diagnosis and a randomly selected mammogram for women with no cancer diagnosis.

^aStable comorbidities are defined as age-related conditions with no influence on predicted 5-year mortality. Examples include arthritis, osteoporosis, depression, diabetes, thyroid disorders, stable coronary artery disease, and peptic ulcer disease (Supplementary Data S1).

^bUnstable comorbidities are defined as life-threatening or difficult to control with less than 5-year predicted mortality. Examples include severe heart failure, end-stage pulmonary disease, end-stage liver disease, renal disease, and diabetes with complications (Supplementary Data S1).

^cMore than 42 months or first screen is defined as a screening mammogram with no prior mammogram within 42 months.

more than 42 months than with shorter intervals of 31–42 months, 19–30 months, or 4–18 months (14.6 vs. 9.9, 8.1, and 6.1 per 1,000 mammograms, respectively).

Advanced-stage cancer rates per 1,000 mammograms were highest among women with unstable comorbidities (1.1; 95% CI, 0.9–1.3) and lower among those with stable comorbidities (0.8; 95% CI, 0.7–0.9) and those with no comorbidities (0.5; 95% CI, 0.3–0.8; Table 5).

Advanced-stage breast cancers were more likely to occur among women with intervals of more than 42 months between mammography examinations compared with shorter intervals of 31–42, 19–30, or 4–18 months (1.7 vs. 1.6, 0.9, and 0.7 per 1,000 mammograms, respectively). The likelihood of diagnosis with advanced-stage cancer was highest among women with unstable comorbidities (1.1; 95% CI, 0.9–1.3) and lower among those with stable (0.8; 95% CI, 0.7–0.9) or no comorbidities (0.5; 95% CI, 0.3–0.8; Table 5). Overall, advanced-stage cancer rates per 1,000 mammograms were significantly higher for women with unstable comorbidities than in women with no comorbidities ($P = 0.002$; Table 5). After stratifying on prior mammography use, the only significant difference across comorbidity groups was that among women with an interval of 4 to 18 months between mammograms. In this group, advanced-stage cancer was more frequent among those with unstable (0.9; 95% CI, 0.7–1.2; $P = 0.004$) and stable comorbidities (0.7; 95% CI, 0.6–0.8; $P = 0.03$) than among those with no comorbidities (0.3; 95% CI, 0.2–0.6).

The mean number of days between mammography and cancer diagnosis was not significantly different between women with stable and unstable comorbidities compared with those with no comorbidities. The mean number of days was 46.8 (95% CI, 39.6–59.9), 54.4 (95% CI, 51.1–57.8), and 50.9 (95% CI, 46.4–55.6) among women with no comorbidities, stable, and unstable comorbidities, respectively.

Discussion

This is a large population-based study of linked BCSC-Medicare data reporting on mammography use and rates of advanced-stage breast cancer relative to presence and severity of comorbidities. It adds to prior research in this field by using better methods to distinguish screening from diagnostic mammograms and to distinguish stable from unstable comorbidities, as the latter may contraindicate offering screening mammography due to limited life expectancy. In adjusted analysis, overall breast cancer rates per 1,000 mammograms did not differ across comorbidity groups, after stratifying by similar mammography use. However, among women who received mammography within 4 to 18 months of diagnosis, advanced-stage cancer rates were significantly higher among those with either unstable or stable comorbidities than among those without comorbidities.

On the basis of prior research (7), we hypothesized that women with unstable comorbidities would be less likely

Table 5. Advanced stage breast cancer rates per 1,000 mammograms by comorbidity status and time to previous mammogram (N = 3,316)

	Overall			4–18 mo			19–30 mo			31–42 mo			>42 mo/first screening ^c		
	Rate (95% CI)	P		Rate (95% CI)	P		Rate (95% CI)	P		Rate (95% CI)	P		Rate (95% CI)	P	
All	0.8 (0.7–0.9)	—		0.7 (0.6–0.8)	—		0.9 (0.7–1.2)	—		1.6 (1.1–2.4)	—		1.7 (1.2–2.4)	—	
No comorbidities	0.5 (0.3–0.8)	Ref		0.3 (0.2–0.6)	Ref		0.4 (0.1–1.5)	Ref		2.2 (0.8–5.9)	Ref		1.3 (0.4–3.9)	Ref	
Stable ^a comorbidities	0.8 (0.7–0.9)	0.065		0.7 (0.6–0.8)	0.03		0.9 (0.6–1.3)	0.803		1.0 (0.5–1.9)	0.024		1.5 (0.9–2.5)	0.422	
Unstable ^b comorbidities	1.1 (0.9–1.3)	0.002		0.9 (0.7–1.2)	0.004		1.0 (0.6–1.6)	0.975		2.7 (1.6–4.7)	0.242		2.2 (1.3–3.9)	0.562	

NOTE: Results adjusted for covariates (age, race/ethnicity/BCSC registry). Mammography use was categorized according to type of examination and time between mammography examination time interval since the prior mammography examination. Time to prior mammogram was calculated using last mammogram before cancer diagnosis for women with a cancer diagnosis and a randomly selected mammogram for women with no cancer diagnosis.

^aStable comorbidities are defined as age-related conditions with no influence on predicted 5-year mortality. Examples include arthritis, osteoporosis, depression, diabetes, thyroid disorders, stable coronary artery disease, and peptic ulcer disease (Supplementary Data S1).

^bUnstable comorbidities are defined as life-threatening or difficult to control with less than 5-year predicted mortality. Examples include severe heart failure, end-stage pulmonary disease, end-stage liver disease, renal disease, and diabetes with complications (Supplementary Data S1).

^cMore than 42 months or first screen is defined as a screening mammogram with no prior mammogram within 42 months.

to undergo mammography and more likely to be diagnosed with advanced-stage disease. Conversely, women with stable comorbidities were hypothesized to be more likely to undergo mammography (4) and less likely to be diagnosed with advanced-stage disease than women without comorbidities. In this cohort, which was limited to women who had at least one mammogram during the study period, we found the expected association between stable comorbidities and increased mammography use but unexpectedly high mammography use among women with unstable comorbidities (e.g., 77.6% of women aged 75 years or older had a mammogram within 30 months) who are less likely to live long enough to benefit from screening. After adjusting for demographic characteristics, stable and unstable comorbidities were associated with 1.60 and 1.14 times higher odds, respectively, than women without comorbidities of having received a prior mammogram within 30 months. Given these findings, we expected stable comorbidities to be associated with lower unadjusted rates of advanced-stage breast cancer and unstable comorbidities to be associated with similar rates, but these associations should diminish or disappear after stratifying on mammography interval (7). In fact, among women who had prior mammography within 4 to 18 months of cancer diagnosis, the rates of advanced-stage cancer were higher among those with either stable or unstable comorbidities than among those without comorbidities.

There are 2 plausible sets of explanations for these findings: health system-related and biologic. Health system-related explanations could be due to delays or errors in mammographic interpretation and delays or errors in diagnostic evaluation after an abnormal mammogram due to competing health care concerns as uncontrolled comorbidities may lead to rescheduling or cancellation of diagnostic tests or difficulties in the referral process. To explore whether advanced-stage disease can be explained by delay in diagnosis, we examined the time interval (mean number of days) between mammography and cancer diagnosis by comorbidity status. We found no statistically significant differences in time to diagnosis among women with no comorbidities compared with those with stable and unstable comorbidities.

Biologic explanations for differences in advanced-stage cancer rates focus on the interaction of aging and comorbidities with cancer risk, disease progression, treatment, and survival (27). Comorbid conditions related to syndromes with common pathophysiologic mechanisms (e.g., metabolic disorders) are associated with more aggressive cancer (28, 29). Diabetes (largely type II diabetes) is associated with a significantly higher risk for breast cancer. A meta-analysis of 20 case-control studies has reported a 20% increased risk of breast cancer [relative risk (RR), 1.20; 95% CI, 1.12–1.28] among women with diabetes versus those no diabetes (30). Hyperinsulinemia is associated with poor disease-specific survival in breast cancer (31). Insulin resistance has been associated with hyperinsulinemia, increased growth factors [including

insulin-like growth factor (IGF)-1], activation of the NF- κ B antiapoptotic pathway via activation of the I κ B kinase β (IKK β), and activation of PPARs (32). Other potential mechanisms are induction of the receptor for advanced glycation end products (RAGE), modulation of the protein kinase B/atypical protein kinase C zeta, and immune mechanisms (32).

Obesity is associated with increased incidence of breast cancer and worse prognosis among postmenopausal women, perhaps due to increased levels of leptin, which can act as a growth factor on cancer cells. Other cytokines that might synergize with leptin are interleukin (IL)-6, IGF-1, and the free portion of IGF-1, which increase with weight (28, 29). Even in the absence of overt diseases, aging is associated with increased levels of several inflammatory markers, such as IL-6, C-reactive protein, and sedimentation rate (33) and nonspecific markers of autoimmunity, such as antinuclear antibodies. Studies examining the interaction of autoimmune disease and cancer among older patients provide conflicting evidence for solid tumors such as breast cancer but do suggest increased incidence of hematologic malignancies (27).

Adequate mammography use among women age ≥ 67 years in this sample (84%) exceeded previously published reports (66%–68%), including a recent report on mammography trends from 2000 to 2008 (68%; refs. 34, 35). Our higher use rates could be because we focused on women who had prior mammography. The prevalence of multiple comorbidities in this study resembled earlier studies using SEER-Medicare data (36) but was somewhat lower than that reported by Fleming and colleagues (7, 12). This difference is probably due to our rigorous classification of ICD-9-CM codes, thus capturing only clinician-assigned diagnoses requiring either multiple outpatient visits or inpatient care.

This is the first large population-based study of the linked BCSC-Medicare data reporting on comorbidities, mammography use among women with and without cancer, and advanced breast cancer rates among older women by comorbidity status. Its strengths include better ascertainment of screening mammography than is possible from claims data alone, minimizing misclassification of screening and diagnostic mammograms. This study's other strengths include its large sample size; geographic, racial, and ethnic diversity; and use of 2 years of prior inpatient and outpatient claims to estimate comorbidity burden and severity. These data cover a large population with detailed data on mammography use, cancer diagnosis, and ICD-9-CM codes for comorbid diagnoses. These data are generalizable to older U.S. women with breast cancer, as they reflect community-based usual care for older women.

This study's limitations include potential underreporting of chronic conditions, a well-recognized limitation of administrative data. Because Medicare claims data are collected primarily for payment and the diagnoses on claims come from medical records, comorbidities are not always reported, especially among patients who have

multiple diagnoses and have been seen only as outpatients. This study did not assess longer term outcomes such as mortality and survival. We also did not address patient preferences and values related to stopping mammography, although Satariano and Regland (37) concluded that early diagnosis of breast cancer would confer little or no survival benefits on women with multiple comorbidities.

Conclusions

We found that older women with stable and unstable comorbidities were significantly more likely to have received mammography within the past 30 months than those without comorbidities, although mammography use was high in all groups. Unadjusted rates of advanced-stage cancer were highest among women with unstable comorbidities, intermediate among women with stable comorbidities, and lowest among those with no comorbidities. After stratifying by prior mammography use, women with and without comorbidities did not differ on overall cancer rates. However, both unstable and stable comorbidities were associated with higher rates of advanced-stage disease at diagnosis among older women who had the most frequent use of mammography. The higher rates of advanced-stage tumors among women with comorbidities cannot be explained by differences in their use of mammography. Future studies need to examine whether specific comorbidities affect clinical progression of breast cancer.

Disclosure of Potential Conflicts of Interest

The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Cancer Institute or the NIH. No potential conflicts of interest were disclosed.

Authors' Contributions

Conception and design: S. Yasmeen, P.S. Romano, B.C. Yankaskas, K. Kerlikowske

Development of methodology: S. Yasmeen, P.S. Romano, T. Onega, B.C. Yankaskas, K. Kerlikowske

Acquisition of data (provided animals, acquired and managed patients, provided facilities, etc.): S. Yasmeen, B.M. Geller, T. Onega, B.C. Yankaskas, D.L. Miglioretti, K. Kerlikowske

Analysis and interpretation of data (e.g., statistical analysis, biostatistics, computational analysis): S. Yasmeen, R.A. Hubbard, P.S. Romano, W. Zhu, B.M. Geller, T. Onega, K. Kerlikowske

Writing, review, and/or revision of the manuscript: S. Yasmeen, R.A. Hubbard, P.S. Romano, W. Zhu, B.M. Geller, T. Onega, B.C. Yankaskas, D.L. Miglioretti, K. Kerlikowske

Administrative, technical, or material support (i.e., reporting or organizing data, constructing databases): S. Yasmeen, T. Onega, K. Kerlikowske

Study supervision: S. Yasmeen, K. Kerlikowske

Acknowledgments

The authors thank the participating women, mammography facilities, and radiologists for the data they have provided for this study. A list of the BCSC investigators and procedures for requesting BCSC data for research purposes are provided at: <http://breastscreening.cancer.gov/>.

Grant Support

The work was supported by the National Cancer Institute–funded Breast Cancer Surveillance Consortium (U01CA63740, U01CA86076, U01CA86082, U01CA63736, U01CA70013, U01CA69976, U01CA63731, U01CA70040, and HHSN261201100031C) and the National Cancer Institute–funded grant (R03 CA139567-01 and ORSP No 08-002858). The collection of cancer data used in this study was supported, in part, by

several state public health departments and cancer registries throughout the U.S. For a full description of these sources, please see: <http://breast-screening.cancer.gov/work/acknowledgement.html>.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked

advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Received March 23, 2012; revised June 18, 2012; accepted June 19, 2012; published OnlineFirst June 28, 2012.

References

- Humphrey LL, Helfand M, Chan BKS, Woolf SH. Breast cancer screening: a summary of the evidence for the US Preventive Services Task Force. *Ann Intern Med* 2002;137:347.
- Ries L, Eisner M, Kosary C. SEER cancer statistics review, 1975–2002. Bethesda, MD: National Cancer Institute. Based on November 2004 SEER data submission, posted to the SEER web site 2005.
- Kiefe CI, Funkhouser E, Ph D, Fouad MN, May DS. Chronic disease as a barrier to breast and cervical cancer screening. *J Gen Intern Med* 1998;13:357–65.
- Fleming ST, Pursley HG, Newman B, Pavlov D, Chen K. Comorbidity as a predictor of stage of illness for patients with breast cancer. *Med Care* 2005;43:132.
- Grady KE, Lemkau JP, McVay JM, Reisine ST. The importance of physician encouragement in breast cancer screening of older women* 1. *Prev Med* 1992;21:766–80.
- Smith RA, Cokkinides V, Eyre HJ. Cancer screening in the United States, 2007: a review of current guidelines, practices, and prospects. *CA Cancer J Clin* 2007;57:90–104.
- Yasmeen S, Xing G, Morris C, Chlebowski RT, Romano PS. Comorbidities and mammography use interact to explain racial/ethnic disparities in breast cancer stage at diagnosis. *Cancer* 2011;117:3252–61.
- Wyld L, Garg D, Kumar I, Brown H, Reed M. Stage and treatment variation with age in postmenopausal women with breast cancer: compliance with guidelines. *Br J Cancer* 2004;90:486–91.
- Walter LC, Covinsky KE. Cancer screening in elderly patients. *JAMA* 2001;285:2750.
- Holmes CE, Muss HB. Diagnosis and treatment of breast cancer in the elderly. *CA Cancer J Clin* 2003;53:227–44.
- Mandelblatt J, Saha S, Teutsch S, Hoerger T, Siu AL, Atkins D, et al. The cost-effectiveness of screening mammography beyond age 65 years. *Ann Intern Med* 2003;139:835.
- Fleming ST, Rastogi A, Dmitrienko A, Johnson KD. A comprehensive prognostic index to predict survival based on multiple comorbidities: a focus on breast cancer. *Med Care* 1999;37:601.
- Smith-Bindman R, Quale C, Chu PW, Rosenberg R, Kerlikowske K. Can Medicare billing claims data be used to assess mammography utilization among women ages 65 and older? *Med Care* 2006;44:463.
- Ballard-Barbash R, Taplin SH, Yankaskas BC, Ernster VL, Rosenberg R, Carney PA, et al. Breast Cancer Surveillance Consortium: a national mammography screening and outcomes database. *AJR Am J Roentgenol* 1997;169:1001.
- Kerlikowske K, Walker R, Miglioretti DL, Desai A, Ballard-Barbash R, Buist DSM. Obesity, mammography use and accuracy, and advanced breast cancer risk. *J Natl Cancer Inst* 2008;100:1724.
- BCSC Glossary of Terms. Available from: http://breastscreening.cancer.gov/data/bcsc_data_definitions.pdf. 2009Sep16, website.doc accessed May 18, 2012.
- Warren JL, Klabunde CN, Schrag D, Bach PB, Riley GF. Overview of the SEER- Medicare data: content, research applications, and generalizability to the United States elderly population. *Med Care* 2002;40:IV-3-18.
- Smith-Bindman R, Miglioretti DL, Lurie N, Abraham L, Barbash RB, Strzelczyk J, et al. Does utilization of screening mammography explain racial and ethnic differences in breast cancer? *Ann Intern Med* 2006;144:541.
- Klabunde CN, Potosky AL, Legler JM, Warren JL. Development of a comorbidity index using physician claims data. *J Clin Epidemiol* 2000;53:1258–67.
- Elixhauser A, Steiner C, Harris DR, Coffey RM. Comorbidity measures for use with administrative data. *Med Care* 1998;36:8.
- Klabunde CN, Harlan LC, Warren JL. Data sources for measuring comorbidity: a comparison of hospital records and Medicare claims for cancer patients. *Med Care* 2006;44:921.
- Klabunde CN, Legler JM, Warren JL, Baldwin LM, Schrag D. A refined comorbidity measurement algorithm for claims-based studies of breast, prostate, colorectal, and lung cancer patients. *Ann Epidemiol* 2007;17:584–90.
- Singletary SE, Connolly JL. Breast cancer staging: working with the sixth edition of the AJCC Cancer Staging Manual. *CA Cancer J Clin* 2006;56:37–47.
- Goldhirsch A, Wood WC, Gelber RD, Coates AS, Thürlimann B, Senn HJ. Meeting highlights: updated international expert consensus on the primary therapy of early breast cancer. *J Clin Oncol* 2003;21:3357.
- Graubard BI, Korn EL. Predictive margins with survey data. *Biometrics* 1999;55:652–9.
- Lane PW, Nelder JA. Analysis of covariance and standardization as instances of prediction. *Biometrics* 1982;38:613–21.
- Extermann M. Interaction between comorbidity and cancer. *Cancer Control* 2007;14:13.
- Carmichael A, Bates T. Obesity and breast cancer: a review of the literature. *Breast* 2004;13:85–92.
- Carmichael A. Obesity and prognosis of breast cancer. *Obesity Rev* 2006;7:333–40.
- Larsson SC, Mantzoros CS, Wolk A. Diabetes mellitus and risk of breast cancer: a meta analysis. *Int J Cancer* 2007;121:856–62.
- Goodwin PJ, Pritchard KI, Ennis M, Clemons M, Graham M, Fantus IG. Insulin-lowering effects of metformin in women with early breast cancer. *Clin Breast Cancer* 2008;8:501–5.
- Komninou D, Ayonote A, Richie JP Jr, Rigas B. Insulin resistance and its contribution to colon carcinogenesis. *Exp Biol Med* 2003;228:396.
- Thomas DR. The relationship between functional status and inflammatory disease in older adults. *J Gerontol Ser A* 2003;58:M995.
- Howard DH, Richardson LC, Thorpe KE. Cancer screening and age in the United States and Europe. *Health Aff* 2009;28:1838.
- Breen N, Gentleman JF, Schiller JS. Update on mammography trends: comparisons of rates in 2000, 2005, and 2008. *Cancer* 2011;117:2209–18.
- McPherson CP, Swenson KK, Lee MW. The effects of mammographic detection and comorbidity on the survival of older women with breast cancer. *J Am Geriatr Soc* 2002;50:1061–8.
- Satariano WA, Ragland DR. The effect of comorbidity on 3-year survival of women with primary breast cancer. *Ann Intern Med* 1994;120:104.